 2. A risk-oriented postremission consolidation phase. The objective was to adopt allogeneic stem cell transplantation alloSCT in high-risk HR cases, while standard-risk SR ones were consolidated with a multicycle high-dose cytarabine-containing program, which included the use of autologous stem cells plus G-CSF to limit drug-related toxicity and intercycle treatment delays. 